J&J Enters Phase 3 Trial for COVID-19 Vaccine
September 25, 2020
BioUtah member Johnson & Johnson (J&J) announced that they’ve started the global phase 3 trial of Janssen’s single-dose vaccine candidate, following phase 1/2 studies that demonstrated safety and immunogenicity.
“As COVID-19 continues to impact the daily lives of people around the world, our goal remains the same – leveraging the global reach and scientific innovation of our company to help bring an end to this pandemic,” said Alex Gorsky, chairman and chief executive officer, Johnson & Johnson.
“This is encouraging news,” said Kelvyn Cullimore, president and CEO of BioUtah. “ We value J&J’s partnership here in Utah and applaud the dedication, science, and expertise they bring to this race for a COVID-19 vaccine.”
J&J has continued to scale up its manufacturing capacity to meet its goal of providing one billion doses of a vaccine each year and has stated that it will provide the vaccine on a not-for-profit basis.
Recent News
- Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
- BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
- Lessons in Innovation: Clark Turner’s Impact on Medical Imaging
- Merit Medical Acquires Biolife Delaware
- Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
